Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  London Stock Exchange  >  Puretech Health PLC    PRTC   GB00BY2Z0H74

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

PureTech Health : Vedanta Biosciences Granted Three New U.S. Patents for Therapeutics Based on Immune-Modulating Bacterial Consortia

share with twitter share with LinkedIn share with facebook
share via e-mail
05/16/2017 | 03:23pm CET

16 May 2017

PureTech Health plc PureTech Health's Vedanta Biosciences Granted Three New U.S. Patents for Therapeutics Based on Immune-Modulating Bacterial Consortia

PureTech Health plc ("PureTech", LSE: PRTC), an advanced, clinical-stage biopharmaceutical company, is pleased to note that the United States Patent and Trademark Office (USPTO) has issued three new patents to Vedanta Biosciences. The latest issuances further strengthen Vedanta Biosciences' leading intellectual property position, broadly covering compositions of matter and methods of use for immune-modulating therapeutic products based on microbiome-derived beneficial clostridium bacteria.

Bharatt Chowrira, President and Chief of Business and Strategy at PureTech Health, said: "These new

U.S. patents further strengthen Vedanta Biosciences' leading global IP portfolio, which includes issuances from the European Patent Office, Japan Patent Office, and the United States Patent and Trademark Office, as well as an exclusive, worldwide license from the University of Tokyo. Along with our proprietary technology platform, industry leading intellectual proprietary portfolio, robust pipeline of bacterial consortia-based therapeutics and GMP manufacturing capabilities, we believe Vedanta is well positioned to deliver on the promise of microbiome-based therapeutics."

The full text of the announcement from Vedanta is as follows:

Vedanta Biosciences Granted Three U.S. Patents Broadly Covering Pharmaceutical Compositions and Methods of Use for Therapeutics Based on Immune-Modulating Bacterial Consortia

CAMBRIDGE, Massachusetts, May 16, 2017- Vedanta Biosciences, pioneering the development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, today announced that the United States Patent and Trademark Office (USPTO) has issued three new patents, 9,642,881, 9,642,882, and 9,649,345. The patents broadly cover compositions of matter and methods of use for therapeutic products based on beneficial clostridium bacteria, further strengthening Vedanta's leading intellectual property position.

"Our pioneering efforts in the development of therapeutics based on immune-modulating bacterial consortia are continuing to be validated through the issuance of additional composition of matter and method of treatment claims worldwide," said Bernat Olle, Ph.D., Chief Executive Officer of Vedanta Biosciences. "The expansion of our intellectual property estate and, in particular, these new patents significantly enhance the value proposition for our pipeline and partnered programs."

The new U.S. patent issuances provide additional support for several programs in Vedanta's pipeline, including therapies for the treatment of Inflammatory Bowel Disease (IBD) and other autoimmune and infectious diseases. They also build on earlier patent issuances from the USPTO, European Patent Office (EPO), and Japan Patent Office (JPO) to further enhance Vedanta's global intellectual property portfolio.

About Vedanta Biosciences

Vedanta Biosciences, a subsidiary of PureTech Health (LSE: PRTC; www.puretechhealth.com), is pioneering development of a novel class of therapies for immune and infectious diseases based on rationally designed consortia of bacteria derived from the human microbiome, with clinical trials expected to begin in 2017. Founded by PureTech Health and a group of world-renowned experts in immunology and microbiology, Vedanta Biosciences is a leader in the microbiome field with capabilities to discover, develop and manufacture drugs based on live bacterial consortia. Leveraging its proprietary technology platform and the expertise of its team of scientific co- founders, Vedanta Biosciences has isolated a vast collection of human-associated bacterial strains and characterised how the immune system recognises and responds to these microbes. This work has led to the identification of human commensal bacteria that induce a range of immune responses - including induction of regulatory T cells and Th17 cells, among others - as well as the characterisation of novel molecular mechanisms of microbial-host communication. These advances have been published in leading peer-reviewed journals including Science, Nature (multiple), Cell and Nature Immunology. Vedanta Biosciences has harnessed these biological insights as well as data from clinical translational collaborations to generate a pipeline of programs in development for infectious disease, autoimmune disease, inflammation and immune-oncology. The clinical potential of therapeutic manipulation of the microbiome has been validated by multiple randomised, controlled trials in infectious disease and inflammatory bowel disease. Vedanta Biosciences has a leading global intellectual property portfolio in the microbiome field with patents issued by the European Patent Office (EPO), Japan Patent Office (JPO) and the United States Patent and Trademark Office (USPTO), and through patent families exclusively licensed worldwide to Vedanta under an agreement with the University of Tokyo.

Vedanta Biosciences' scientific co-founders have pioneered the fields of innate immunity, Th17 and regulatory T cell biology, and include Dr. Ruslan Medzhitov (Professor of Immunobiology at Yale), Dr. Alexander Rudensky (tri-institutional Professor at the Memorial Sloan-Kettering Institute, the Rockefeller University and Cornell University), Dr. Dan Littman (Professor of Molecular Immunology at NYU), Dr. Brett Finlay (Professor at the University of British Columbia) and Dr. Kenya Honda (Professor, School of Medicine, Keio University). Vedanta is backed by PureTech Health, Seventure, Invesco Asset Management, and Rock Springs Capital.

About PureTech Health

PureTech Health (PureTech Health plc, PRTC.L) is an advanced, clinical-stage biopharmaceutical company developing novel medicines that modulate the adaptive human systems. PureTech's therapies target the dysfunctions in the immune, nervous, and gastro-intestinal systems by addressing the underlying pathophysiology of disease from a systems perspective rather than through a single receptor or pathway. The Company is advancing a rich pipeline that includes multiple human proof- of-concept studies and pivotal or registration studies expected to read out over the next 12-18 months. PureTech Health's growing research and development pipeline has been developed in collaboration with some of the world's leading scientific experts, who along with PureTech's experienced team and a stellar Board identify, analyse and advance very selectively the opportunities the Company believes hold the most promise for patients. This experienced and engaged team places PureTech Health at the forefront of ground-breaking science and technological innovation and leads

the Company between and beyond existing disciplines. For more information, visit

www.puretechhealth.com or connect with us on Twitter @puretechh.

Forward Looking Statement

This press release contains statements that are or may be forward-looking statements, including statements that relate to the company's future prospects, developments and strategies. The forward- looking statements are based on current expectations and are subject to known and unknown risks and uncertainties that could cause actual results, performance and achievements to differ materially from current expectations, including, but not limited to, those risks and uncertainties described in the risk factors included in the regulatory filings for PureTech Health plc. These forward-looking statements are based on assumptions regarding the present and future business strategies of the company and the environment in which it will operate in the future. Each forward-looking statement speaks only as at the date of this press release. Except as required by law and regulatory requirements, neither the company nor any other party intends to update or revise these forward-looking statements, whether as a result of new information, future events or otherwise.

Contact: PureTech Health FTI Consulting

Allison Mead

+1 617 651 3156

[email protected]

Ben Atwell, Matthew Cole, Rob Winder

+44 (0) 20 3727 1000

PureTech Health plc published this content on 16 May 2017 and is solely responsible for the information contained herein.
Distributed by Public, unedited and unaltered, on 16 May 2017 13:22:25 UTC.

share with twitter share with LinkedIn share with facebook
share via e-mail
01/29RESTORBIO : BioCentury - resTORbio raises $85M IPO
01/26PURETECH HEALTH : Affiliate resTORbio Announces Pricing of Initial Public Offeri..
01/03PURETECH HEALTH : Affiliate resTORbio Adds Lynne Sullivan, Biogen Senior Vice Pr..
01/03PURETECH HEALTH : resTORbio Appoints Lynne Sullivan to Its Board of Directors
01/02PURETECH HEALTH : Affiliate resTORbio Files Public Registration Statement for Pr..
2017PURETECH HEALTH : Affiliate Entrega to Receive $5 Million for Eli Lilly Collabor..
2017PURETECH HEALTH : Entrega To Receive $5 Million Investment from Lilly To Advance..
2017ENTREGA : To Receive $5 Million Investment from Lilly To Advance Proprietary Ora..
2017PURETECH HEALTH : Vedanta Biosciences Granted Four New US Patents Expanding Cove..
2017VEDANTA BIOSCIENCES : Granted Four New U.S. Patents Expanding Coverage for Compo..
More news
Financials ($)
Sales 2017 1,58 M
EBIT 2017 -121 M
Net income 2017 -89,8 M
Finance 2017 23,9 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 348x
EV / Sales 2018 160x
Capitalization 572 M
Duration : Period :
Puretech Health PLC Technical Analysis Chart | PRTC | GB00BY2Z0H74 | 4-Traders
Technical analysis trends PURETECH HEALTH PLC
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus BUY
Number of Analysts 5
Average target price 3,49 $
Spread / Average Target 46%
EPS Revisions
Daphne Zohar Chief Executive Officer & Executive Director
Bharatt M. Chowrira President, Chief Business & Strategy Officer
Joichi Ito Non-Executive Chairman
Stephen Muniz Chief Operations Officer, Secretary & Director
Eric Elenko Chief-Research & Strategy
Sector and Competitors
1st jan.Capitalization (M$)
CELLTRION, INC.--.--%35 080
LONZA GROUP-6.95%19 560